OCULAR THERAPEUTIX, INC (OCUL) research

OCULAR THERAPEUTIX, INC
ShareXLinkedInReddit
Sector
Pharmaceuticals
Last price
$9.99
As of

OCULAR THERAPEUTIX, INC (OCUL): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-03.

As of . Source: SEC EDGAR filings for OCUL. Method and limitations.

SHARE THIS CARD

Share the OCUL intelligence card

A branded snapshot of OCUL: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion OCUL intelligence card preview
Post to X
LIVE TERMINAL

See OCUL live in the terminal

Track OCUL's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live OCUL terminal, free

Active signals for OCUL

FREE, NO ACCOUNT

Every signal on OCUL, as it fires

You are seeing 5 of 21 signals recorded on OCUL since 2026-06-03.

The five above all landed on 2026-09-06. The other 16 were recorded on 4 other days. 17 of the 21 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in OCUL (2026Q2)

Manager / securityMarket value% portfolioQoQ
Point72 Asset Management, L.P.CUSIP 67576A100 · 2026Q2$32.3M0.04%,
TWO SIGMA INVESTMENTS, LPCUSIP 67576A100 · 2026Q2$12M0.01%,
RENAISSANCE TECHNOLOGIES LLCCUSIP 67576A100 · 2026Q2$3.7M0.01%,
CITADEL ADVISORS LLCCUSIP 67576A100 · 2026Q2$3M0.00%,
D. E. Shaw & Co., Inc.CUSIP 67576A100 · 2026Q2$1.2M0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, OCUL

OCUL against its peers

OCUL's operating margin of -519.8% ranks in the 12th percentile of 19 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.

MetricOCULPeer medianPercentilen
Revenue FY52.0M USD638M USD1621
Gross marginn/a53.3%n/a7
Operating margin-519.8%8.5%1319
Net margin-511.9%0.6%1220
Return on equity-40.6%-9.3%3921
P / En/a14.9xn/a10

Peers (25): NKTR, SUPN, BHC, TRVI, HRMY, GPCR, NUVB, ANIP, INVA, OGN, AMLX, TARS, XERS, PAHC, OMER, ANRO, ALMS, AMPH, PCRX, LQDA, AMRX, ESPR, ACRS, COLL, AXSM. Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (OCUL: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more OCUL signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to OCULand get the insider, 13F, options, and confluence read in one view.

Open the live OCUL terminal, free